Mark Chiu | President
Tavotek Biotherapeutics | United States

Mark is the Chief Scientific Officer at Tavotek Biotherapeutics.  He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Chiu was the Head of the Process Analytical Sciences at Biotherapeutics Development and Head of Antibody Engineering in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (JNJ). His leadership resulted in more than 15 New Molecular Entities with 6 projects transitioning from Phase 1 to Phase 3 trials with 4 approved drugs.  Dr. Chiu received his A.B. in Biophysics from University of California at Berkeley;  Ph.D. degree from the University of Illinois at Urbana-Champaign, and then completed postdoctoral training at the Laboratory of Physical Chemistry at the Federal Institute of Technology at Zurich, Switzerland and the Department of Microbiology at the University of Basel Biocentre.